Literature DB >> 8222328

Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor.

M Kristensen1, C Q Chu, D J Eedy, M Feldmann, F M Brennan, S M Breathnach.   

Abstract

The distribution of TNF-alpha, p55 TNF receptor (TNF-R) and p75 TNF-R in normal skin and uninvolved and lesional skin from psoriasis patients has been investigated, using specific mono- and polyclonal antibodies. In normal skin, and uninvolved and lesional skin from psoriasis patients, p55 TNF-R is associated with epidermal keratinocytes and a network of upper dermal dendritic cells. This suggests that the actions of TNF-alpha on epidermal cells in vivo are mediated by binding to the p55 TNF-R. In lesional psoriasis skin, there was staining of the parakeratotic stratum corneum and increased expression of p55 TNF-R in association with upper dermal blood vessels. Staining for p75 TNF-R in normal skin was restricted to eccrine sweat ducts and dermal dendritic cells, and was absent from the epidermis. In lesional psoriasis skin, there was staining for p75 TNF-R in association with upper dermal blood vessels and perivascular infiltrating cells. TNF-alpha in normal skin was predominantly localized to the basal cell layers of the epidermis, and was seen in association with eccrine ducts and sebaceous glands. In lesional psoriasis skin, and to a lesser extent in uninvolved psoriasis skin, TNF-alpha was distributed throughout the epidermis, and was also specifically localized to upper dermal blood vessels. Up-regulation of TNF-alpha, p55 TNF-R and p75 TNF-R on dermal blood vessels in psoriasis may play an important role in the pathogenesis of this condition by promoting cutaneous recruitment of inflammatory cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8222328      PMCID: PMC1534247          DOI: 10.1111/j.1365-2249.1993.tb03457.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

1.  Elastic properties of human skin: relation to age, sex, and anatomical region.

Authors:  A B Cua; K P Wilhelm; H I Maibach
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

2.  Systemic TNF administration in psoriatic patients: a promising therapeutic modality for severe psoriasis.

Authors:  H Takematsu; H Ozawa; T Yoshimura; M Hara; A Sakakibara; J Oyama; H Tagami
Journal:  Br J Dermatol       Date:  1991-02       Impact factor: 9.302

3.  Effect of tumour necrosis factor in the mouse-tail model of psoriasis.

Authors:  K Nagano; K Hori; T Nagane; T Sugawara; J Oh-ishi; H Hayashi; N Watanabe; Y Niitsu
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

Review 4.  Keratinocytes as initiators of inflammation.

Authors:  J N Barker; R S Mitra; C E Griffiths; V M Dixit; B J Nickoloff
Journal:  Lancet       Date:  1991-01-26       Impact factor: 79.321

5.  Production of interleukin-8 by human dermal fibroblasts and keratinocytes in response to interleukin-1 or tumour necrosis factor.

Authors:  C G Larsen; A O Anderson; J J Oppenheim; K Matsushima
Journal:  Immunology       Date:  1989-09       Impact factor: 7.397

6.  Production of interleukin-1 and interleukin-6 by human keratinocytes and squamous cell carcinoma cell lines.

Authors:  M Partridge; D Chantry; M Turner; M Feldmann
Journal:  J Invest Dermatol       Date:  1991-05       Impact factor: 8.551

7.  Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis.

Authors:  B J Nickoloff; G D Karabin; J N Barker; C E Griffiths; V Sarma; R S Mitra; J T Elder; S L Kunkel; V M Dixit
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

8.  Human dermal mast cells contain and release tumor necrosis factor alpha, which induces endothelial leukocyte adhesion molecule 1.

Authors:  L J Walsh; G Trinchieri; H A Waldorf; D Whitaker; G F Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

9.  Independent regulation of 55-kDa and 75-kDa tumor necrosis factor receptors during activation of human peripheral blood B lymphocytes.

Authors:  B K Erikstein; E B Smeland; H K Blomhoff; S Funderud; K Prydz; W Lesslauer; T Espevik
Journal:  Eur J Immunol       Date:  1991-04       Impact factor: 5.532

10.  Tumor necrosis factor is a critical mediator in hapten induced irritant and contact hypersensitivity reactions.

Authors:  P F Piguet; G E Grau; C Hauser; P Vassalli
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

View more
  27 in total

Review 1.  Tumor necrosis factor-α signaling in macrophages.

Authors:  Narayanan Parameswaran; Sonika Patial
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2010       Impact factor: 1.807

2.  UVB-induced association of tumor necrosis factor (TNF) receptor 1/TNF receptor-associated factor-2 mediates activation of Rel proteins.

Authors:  D Tobin; M van Hogerlinden; R Toftgård
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-20       Impact factor: 11.205

3.  Hairy leukoplakia: an unusual combination of transforming and permissive Epstein-Barr virus infections.

Authors:  J Webster-Cyriaque; J Middeldorp; N Raab-Traub
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

4.  Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease.

Authors:  Juliane Totzke; Deepak Gurbani; Rene Raphemot; Philip F Hughes; Khaldon Bodoor; David A Carlson; David R Loiselle; Asim K Bera; Liesl S Eibschutz; Marisha M Perkins; Amber L Eubanks; Phillip L Campbell; David A Fox; Kenneth D Westover; Timothy A J Haystead; Emily R Derbyshire
Journal:  Cell Chem Biol       Date:  2017-08-17       Impact factor: 8.116

Review 5.  Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders.

Authors:  Jacqueline M Benson; David Peritt; Bernard J Scallon; George A Heavner; David J Shealy; Jill M Giles-Komar; Mary Ann Mascelli
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

6.  Effect of Adalimumab on Gene Expression Profiles of Psoriatic Skin and Blood.

Authors:  Maggie Chow; Kevin Lai; Richard Ahn; Rashmi Gupta; Sarah Arron; Wilson Liao
Journal:  J Drugs Dermatol       Date:  2016-08-01       Impact factor: 2.114

7.  Dual Inhibition of TNFR1 and IFNAR1 in Imiquimod-Induced Psoriasiform Skin Inflammation in Mice.

Authors:  Lynda Grine; Lien Dejager; Claude Libert; Roosmarijn E Vandenbroucke
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

8.  Persistent inflammation and angiogenesis during wound healing in K14-directed Hoxb13 transgenic mice.

Authors:  Judith A Mack; Edward V Maytin
Journal:  J Invest Dermatol       Date:  2009-09-17       Impact factor: 8.551

Review 9.  Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases.

Authors:  Leanne M Johnson-Huang; N Scott McNutt; James G Krueger; Michelle A Lowes
Journal:  J Clin Immunol       Date:  2009-02-28       Impact factor: 8.317

10.  Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature.

Authors:  Jochen Schmitt; Gottfried Wozel
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.